November 6, 2025 Q1 FY26 Results Presentation 1 Regulatory Disclosures 2 Safe Harbor Statement 3 US GAAP Income Statement for the Quarter | | ZAR'000 | | | | $'000 | | | --- | --- | --- | --- | --- | --- | --- | | | | | % Growth | | | % Growth | | Q1 - ended 30 September | FY26 Q1 | FY25 Q1 | YoY | FY26 Q1 | FY25 Q1 | YoY | | Average exchange rate for conversion from ZAR to $ | R17,67 | R17,72 | (0%) | R17,67 | R17,72 | (0%) | | Revenue | 3 023 546 | 2 756 877 | 10% | 171 448 | 153 568 | 12% | | Expense | ( ...

Drive for better vision : HIMX November 2025 INVESTOR PRESENTATION Forward Looking Statements Factors that could cause actual events or results to differ materially from those described in this conference call include, but are not limited to, the effect of the Covid-19 pandemic on the Company's business; general business and economic conditions and the state of the semiconductor industry; market acceptance and competitiveness of the driver and non-driver products developed by the Company; demand for end-use ...

Third Quarter 2025 Earnings Report Speakers: DAVE GILBOA | Co-Founder & Co-CEO NEIL BLUMENTHAL | Co-Founder & Co-CEO STEVE MILLER | SVP & Chief Financial Officer Speakers: DAVE GILBOA | Co-Founder & Co-CEO NEIL BLUMENTHAL | Co-Founder & Co-CEO JOSH TRUPPO | VP, Financial Planning & Analysis Forward-Looking Statements / Non-GAAP Financial Measures ................ This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E ...

© Commerce. All rights reserved. Confidential. 3Q 2025 Earnings Presentation DISCLAIMER This presentation has been prepared by Commerce.com, Inc. ("we," "us," "our," "Commerce," "Commerce.com" or the "Company"). This presentation may contain forward-looking statements which constitute the views of the Company with respect to future events which can be identified by the use of forward-looking terminology such as "anticipate," "believe," "budget," "can," "continue," "commit," "control," "could," "estimate," " ...

Q2 2025 Results Gleb Budman CEO and Co-Founder Backblaze Marc Suidan CFO August 7, 2025 Backblaze ©2024 Confidential | 1 Important Information About This Presentation Cautionary Note Regarding Forward-Looking Statements This presentation contains forward-looking statements, which involve risks and uncertainties. These forward-looking statements are generally identified by the use of forward-looking terminology, including the terms "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," ...

Q3 2025 Earnings Report November 6, 2025 | Nasdaq: COLL Healthier people. Stronger communities. Forward-Looking Statements This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. We may, in some cases, use terms such as "predicts," "forecasts," "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "should" or other words that convey uncertainty of future ev ...

This presentation contains certain "forward -looking statements" based on management's current expectations. Forward -looking stat ements include, but are not limited to, the statements under "Financial Outlook," statements regarding long term performance, statements regarding the Company's capital deployment plans, including anticipated annual dividend rates and share repurchase plans, and statements that can be identified by the use of forward -looking terminology such as "may," "can," "if," "continue," " ...

业绩总结 - 2025年9个月和第三季度总收入为43236百万美元，同比增长11%[21] - 第三季度总收入为15191百万美元，同比增长10%[21] - 2025年9个月的核心每股收益为7.04美元，同比增长15%[22] - 2025年9个月的毛利率为83%，较去年增加1个百分点[21] - 2025年9个月的研发费用为10370百万美元，同比增长16%[21] - 2025年9个月的净债务为246亿美元，EBITDA为194亿美元[23] - 2025年9个月的税率为19%[21] 用户数据 - 肿瘤学部门2025年9个月总收入为186亿，增长16%[28] - BioPharmaceuticals部门2025年9个月总收入为171亿美元，同比增长5%[37] - Rare Disease部门2025年9个月总收入为68亿美元，同比增长6%[48] - Tagrisso需求增长10%，在1L联合市场中保持领导地位[33] - Calquence需求增长11%，巩固了在主要市场1L CLL中的BTKi领先地位[33] - Lynparza PR需求增长5%，持续保持PARPi领导地位[33] - Truqap需求增长54%，在2L生物标志物改变人群中持续增长[33] - Imfinzi需求增长31%，在肺癌和膀胱癌中强劲推出[33] - Enhertu需求增长39%，在CTx-naïve HER2-low mBC中吸引力增加[33] - Ultomiris需求增长17%，在竞争激烈的gMG和PNH市场中需求增长[54] - Koselugo需求增长79%，在新兴市场中受到强劲需求和有利时机的推动[54] 新产品和新技术研发 - 2025年9个月内，AstraZeneca的总收入由产品销售、联盟收入和合作收入组成[76] - 2025年9个月内，产品收入达到53.52亿美元，同比增长10%[84] - Lynparza在2025年9个月内的收入为24.01亿美元，同比增长7%[87] - Imfinzi在2025年9个月内的收入为43.17亿美元，同比增长25%[90] - Enhertu在2025年9个月内的收入为19.76亿美元，同比增长38%[97] - Imjudo在2025年9个月内的收入为2.53亿美元，同比增长21%[91] 未来展望 - 2025年预计总收入将以高单位数百分比增长[24] - 预计2025年全球非小细胞肺癌患者人数为150,000[78] - 预计2025年全球乳腺癌患者人数为540,000[80] 其他新策略和有价值的信息 - Farxiga在2025年9个月内实现11%的增长，收入为63.45亿美元[103] - Brilinta在2025年9个月内下降33%，收入为6.65亿美元[103] - Lokelma在2025年9个月内增长31%，收入为5.17亿美元[103] - Fasenra在2025年9个月内增长19%，收入为14.51亿美元[106] - Tezspire在2025年9个月内增长63%，收入为7.70亿美元[106] - Saphnelo在2025年9个月内增长47%，收入为4.83亿美元[106] - Ultomiris在2025年9个月内增长21%，收入为34.53亿美元[115] - Strensiq在2025年9个月内增长19%，收入为11.88亿美元[115] - Koselugo在2025年9个月内增长34%，收入为4.98亿美元[115] - Symbicort在2025年9个月内下降0%，收入为21.80亿美元[110]

Disclaimer Unless the context otherwise provides, "we," "us," "our," "CRH", the "Company" and like terms refer to CRH plc and its consolidated subsidiaries. Forward-Looking Statements In order to rely upon the "Safe Harbor" provisions of the United States Private Securities Litigation Reform Act of 1995, CRH is providing the following cautionary statement. This presentation contains statements that are, or may be deemed to be, forward-looking statements with respect to the financial condition, results of op ...

Q4 FY25 Earnings Presentation Advancing the world of healthTM Caution Concerning Forward-looking Statements This presentation and accompanying webcast contain certain estimates and other forward-looking statements (as defined under Federal securities laws) regarding BD's future prospects and performance, including, but not limited to, future revenues, margins, earnings per share, leverage targets, capital deployment and the proposed combination of BD's Biosciences and Diagnostic Solutions business with Wate ...